Liver Cirrhosis
Conditions
Brief summary
This study is a prospective study. We signed an informed consent form with patients with liver fibrosis and took tauroursodeoxycholic acid orally for half a year. After half a year, liver biopsy was performed using histopathology, immunohistochemistry, and polymerase chain reaction, Western blotting method was used to determine the expression level of fibrosis-related markers to verify the effect of taurodeoxycholic acid on patients with liver fibrosis.
Detailed description
Tauroursodeoxycholic acid is an effective component of bear bile, which has obvious curative effects in the treatment of gallstones and liver diseases. In recent years, the research field of tauroursodeoxycholic acid has been very active, and its chemical synthesis has also attracted much attention. The usage is swallowing with water before going to bed at night. It must be taken regularly, one capsule at a time (250mg), once a day. After 6 months of continuous use, liver biopsy was performed after 6 months. Telling the patient to swallow with water before going to bed at night. It must be taken regularly, one capsule at a time (250mg), once a day. After 6 months of continuous use, liver B-ultrasound biopsy was performed to observe the effect.
Interventions
Oral TUDCA, once a day, one tablet (250mg) at a time for 6 months
DRUGPlacebo
Oral placebo, once a day, one tablet at a time for 6 months
Sponsors
The First Affiliated Hospital with Nanjing Medical University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
30 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Clinical diagnosis of liver cirrhosis and liver fibrosis in patients requiring medical treatment.
Exclusion criteria
* Patients with end-stage cirrhosis, liver failure, etc. who need liver transplantation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Liver biopsy | up to 24 weeks | Synthesis of liver extracellular matrix（Synthesis, degradation） |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Liver ultrasound | up to 24 weeks | Liver parenchymal echo（Normal, dense, thickened） |
Outcome results
None listed